Exact Sciences — Nov 3, 2025 release

sspanos@exactsciences.com 608-556-4380   For Immediate Release   Exact Sciences Announces Third Quarter 2025 Results Reports record revenue, raises full-year guidance, generates record cash from operations Third quarter and recent highlights • Delivered record total third quarter revenue of $851 million, an increase of 20% on a reported and core revenue basis, including Screening revenue of $666 million and Precision Oncology revenue of $184 million • Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $78 million and $10 million, respectively • Generated record cash from operations and free cash flow • Launched Cancerguard ® , the company's multi-cancer early detection test, for patients in the United States MADISON, Wis. , November 3, 2025 — Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $851 million for the third quarter ended September 30, 2025, compared to $709 million for the same period of 2024.   “Exact Sciences continues to advance our mission to prevent cancer and detect it earlier through a relentless focus on patients,” said Kevin Conroy, chairman and CEO. “Our third quarter results reflect the power of our patient-centric platform and our trusted brands, Cologuard® and Oncotype DX®. The momentum we are building is fueling growth, advancing innovative new tests like Cancerguard, and strengthening our financial performance." Third quarter 2025 financial results For the three-month period ended September 30, 2025, as compared to the same period of 2024 (where applicable): • Total revenue was $851 million, an increase of 20% on a reported and core revenue basis • Screening revenue was $666 mill